חזרה לתוצאות החיפוש

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Chronic Spontaneous Urticaria

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Kern Research, Bakersfield, California, United States

    Contact: Study coordinator (Wandy Noriega) · wandy.noriega@kernresearch.com · 661-864-7710
    Contact: Principal Investigator (Eric Boren)

  • Allergy and Asthma Medical Group and Research Center, San Diego, California, United States

    Contact: Study coordinator (Susan Smith) · susansmith@allergyandasthma.com · 858-268-2368
    Contact: Principal Investigator (Bob Geng)

  • Pediatric Dermatology of Miami at the Pediatric CoE, Miami, Florida, United States

    Contact: Study coordinator (Andrea Marin) · andrea@pediatricskinresearch.com · 305-667-3152
    Contact: Principal Investigator (Mercedes E Gonzalez)

  • Treasure Valley Medical Research, Boise, Idaho, United States

  • Endeavor Health, Glenview, Illinois, United States

  • Allergy and Asthma Specialist P S C, Owensboro, Kentucky, United States

    Contact: Study coordinator (Angela Haynes) · ahaynes@cloremd.com · 270-684-6144
    Contact: Principal Investigator (Lee Clore)

  • Toledo Institute of Clinical Research, Toledo, Ohio, United States

  • Allergy Asthma and Clinical Research, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Meryem Assaoui) · meryem@mtarpay.com · 405-752-0393
    Contact: Principal Investigator (Martha Tarpay)

  • Allergy and Clinical Immunology Associates, Pittsburgh, Pennsylvania, United States

  • RFSA Dermatology, San Antonio, Texas, United States

    Contact: Study coordinator (Jonathan Joseph) · jvjoseph007@gmail.com
    Contact: Principal Investigator (Lindsey Finklea)

  • Allergy Associates of Utah, Sandy City, Utah, United States

  • Seattle Allergy and Asthma Rsch, Seattle, Washington, United States

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, Caba, Buenos Aires, Argentina

  • Novartis Investigative Site, Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site, Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, San Miguel de Tucumán, Argentina

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Tübingen, Germany

  • Novartis Investigative Site, Hong Kong, Hong Kong

  • Novartis Investigative Site, Hong Kong, Hong Kong

  • Novartis Investigative Site, Bari, BA, Italy

  • Novartis Investigative Site, Florence, FI, Italy

  • Novartis Investigative Site, Parma, PR, Italy

  • Novartis Investigative Site, Pavia, PV, Italy

  • Novartis Investigative Site, Siena, SI, Italy

  • Novartis Investigative Site, Trieste, TS, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Kitakyushu, Fukuoka, Japan

  • Novartis Investigative Site, Kamimashi-gun, Kumamoto, Japan

  • Novartis Investigative Site, Sakai, Osaka, Japan

  • Novartis Investigative Site, Izumo, Shimane, Japan

  • Novartis Investigative Site, Itabashi-ku, Tokyo, Japan

  • Novartis Investigative Site, Kuching, Sarawak, Malaysia

  • Novartis Investigative Site, Deventer, Overijssel, Netherlands

  • Novartis Investigative Site, Utrecht, Netherlands

  • Novartis Investigative Site, Lodz, Poland

  • Novartis Investigative Site, Olsztyn, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Pretoria, Gauteng, South Africa

  • Novartis Investigative Site, Cape Town, South Africa

  • Novartis Investigative Site, Esplugues, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Songkhla, Hat Yai, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Sihhiye-Altindag, Turkey (Türkiye)

  • Novartis Investigative Site, Adana, Turkey (Türkiye)

  • Novartis Investigative Site, Peterborough, Cambridgeshire, United Kingdom

  • Novartis Investigative Site, Manchester, United Kingdom

  • Novartis Investigative Site, Southampton, United Kingdom

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)